AI Science Tracker

Mount Sinai

1 discovery from 2020

Discoveries

Mount Sinai

AI and clinical data to identify COVID-19 from CT scans

In a test on 279 patients, a system combining CT scans and clinical information reached 84% sensitivity, compared with 75% for radiologists in the reported comparison. Retrospective study on data collected in China, without evidence of effectiveness in prospective clinical use.

Technology: Multimodal deep learning

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Trained on 626 of 905 patients and tested on the remaining 279 against radiologists: sensitivity 84% versus 75%, AUC 0.92, and 68% of RT-PCR-positive cases with normal CT correctly identified.
  • Still unknown: Intended for use when CT scans and clinical history are both available; CT alone may have limited negative predictive value; prospective clinical use not evaluated; specificity not reported.
  • AI role: Combined chest CT findings with clinical symptoms, exposure history and lab results to identify COVID-19-positive patients.

Evidence sources: https://www.mountsinai.org/about/newsroom/2020/mount-sinai-first-in-us-to-use-artificial-intelligence-to-analyze-coronavirus-covid19-patients-pr · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-020-0931-3&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 1114 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.